GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lee, Eui Jin ^a,d   Kang, Guhyun ^a,b   Kang, Shin Woo ^a,c   Jang, Kee Taek ^a   Lee, Jeeyun ^a   Park, Joon Oh ^a   Park, Cheol Keun ^a   Sohn, Tae Sung ^a   Kim, Sung ^a   Kim, Kyoung Mee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE T1; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SOMATOMEDIN C RECEPTOR; SUCCINATE DEHYDROGENASE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME DELETION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DIGESTIVE SYSTEM CANCER; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GSTT1 GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IGF1R GENE; KIT GENE; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; ONCOGENE; PDGFRA GENE; SDH GENE; SDHB GENE; TREATMENT RESPONSE; VEGF GENE; ZNF GENE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; ZINC FINGERS;

EID: 84885048347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077219     Document Type: Article

References (35)

1. Corless CL, Barnett CM, Heinrich MC, (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11: 865-878. PubMed: 22089421.
2. Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, et al. (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10: 1045-1052. doi:10.1016/S1470-2045(09)70242-6. PubMed: 19793678.
3. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338. doi:10.1016/S0140-6736(06)69446-4. PubMed: 17046465.
4. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol Off J American Society Of Clinical Oncology 21: 4342-4349. doi:10.1200/JCO.2003.04.190. PubMed: 14645423.
5. Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU, (2007) Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch Int J Pathol 451: 743-749. doi:10.1007/s00428-007-0473-9. PubMed: 17701051.
6. Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, et al. (2007) Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67: 9084-9088. doi:10.1158/0008-5472.CAN-07-1938. PubMed: 17909012.
7. Corless CL, Fletcher JA, Heinrich MC, (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825. doi:10.1200/JCO.2004.05.140. PubMed: 15365079.
8. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, et al. (2008) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res Off J Am Assoc Cancer Res 14: 3204-3215. doi:10.1158/1078-0432.CCR-07-1984. PubMed: 18483389.
9. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360-5367. doi:10.1200/JCO.2008.17.4284. PubMed: 18955451.
10. Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, et al. (2009) Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 52: 767-771. doi:10.1002/pbc.21909. PubMed: 19326424.
11. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, et al. (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol Off J American Society Of Clinical Oncology 26: 5352-5359. doi:10.1200/JCO.2007.15.7461. PubMed: 18955458.
12. Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, et al. (2009) Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 8: 2172-2182. doi:10.1158/1535-7163.MCT-09-0193. PubMed: 19671739.
13. Assämäki R, Sarlomo-Rikala M, Lopez-Guerrero JA, Lasota J, Andersson LC, et al. (2007) Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors. Genes Chromosomes Cancer 46: 564-576. doi:10.1002/gcc.20439. PubMed: 17330260.
14. Gunawan B, von Heydebreck A, Sander B, Schulten HJ, Haller F, et al. (2007) An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 211: 463-470. doi:10.1002/path.2128. PubMed: 17226762.
15. Wozniak A, Sciot R, Guillou L, Pauwels P, Wasag B, et al. (2007) Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer 46: 261-276. doi:10.1002/gcc.20408. PubMed: 17171690.
16. Chen Y, Tzeng CC, Liou CP, Chang MY, Li CF, et al. (2004) Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J Biomed Sci 11: 65-71. doi:10.1007/BF02256550. PubMed: 14730211.
17. Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, et al. (2007) Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol 31: 224-232. doi:10.1097/01.pas.0000213318.66800.94. PubMed: 17255767.
18. Rouveirol C, Stransky N, Hupé P, Rosa PL, Viara E, et al. (2006) Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics 22: 849-856. doi:10.1093/bioinformatics/btl004. PubMed: 16434445.
19. Bardella C, Pollard PJ, Tomlinson I, (2011) SDH mutations in cancer. Biochim Biophys Acta 1807: 1432-1443. doi:10.1016/j.bbabio.2011.07.003. PubMed: 21771581.
20. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, et al. (2010) A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest J Tech Methods Pathol 90: 1285-1294. doi:10.1038/labinvest.2010.110. PubMed: 20548289.
21. Yang J, Du X, Lazar AJ, Pollock R, Hunt K, et al. (2008) Genetic aberrations of gastrointestinal stromal tumors. Cancer 113: 1532-1543. doi:10.1002/cncr.23778. PubMed: 18671247.
22. Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, et al. (2009) High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer 48: 886-896. doi:10.1002/gcc.20689. PubMed: 19585585.
23. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, et al. (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 108: 314-318. doi:10.1073/pnas.1105216108. PubMed: 21173220.
24. Pantaleo MA, Astolfi A, Indio V, Moore R, Thiessen N, et al. (2011) SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 103: 983-987. doi:10.1093/jnci/djr130. PubMed: 21505157.
25. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, et al. (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res Off J Am Assoc Cancer Res 10: 3282-3290. doi:10.1158/1078-0432.CCR-03-0715. PubMed: 15161681.
26. Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, et al. (2008) The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle 7: 2949-2955. doi:10.4161/cc.7.19.6760. PubMed: 18818517.
27. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, et al. (2008) Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105: 8387-8392. doi:10.1073/pnas.0803383105. PubMed: 18550829.
28. Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, et al. (2006) Gene expression signatures associated with the resistance to imatinib. Leukemia 20: 1542-1550. doi:10.1038/sj.leu.2404310. PubMed: 16855633.
29. Rink L, Ochs MF, Zhou Y, von Mehren M, Godwin AK, (2013) ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor. PLOS ONE 8: e54477. doi:10.1371/journal.pone.0054477. PubMed: 23372733.
30. Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S, (2011) Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 8: 161-170. doi:10.1038/nrclinonc.2011.3. PubMed: 21364689.
31. Frova C, (2006) Glutathione transferases in the genomics era: new insights and perspectives. Biomolecular engineering 23: 149-169.
32. McIlwain CC, Townsend DM, Tew KD, (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648. doi:10.1038/sj.onc.1209373. PubMed: 16550164.
33. Hayes JD, Pulford DJ, (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600. doi:10.3109/10409239509083491. PubMed: 8770536.
34. Koh Y, Kim DY, Park SH, Jung SH, Park E, et al. (2010) GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. Cancer Genet Cytogenet 203: 215-221. doi:10.1016/j.cancergencyto.2010.08.022. PubMed: 21156236.
35. Kang HJ, Koh KH, Yang E, You KT, Kim HJ, et al. (2006) Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 6: 1151-1157. doi:10.1002/pmic.200500372. PubMed: 16402362.